Evaluating Hematuria

Hematuria, while often benign, requires systematic evaluation to rule out underlying malignancies in the genitourinary tract. Microscopic hematuria—defined as three or more red blood cells per high-power field—necessitates microscopic confirmation rather than relying solely on dipstick results. Dr. Aaron Potretzke, a urologist at the Mayo Clinic, emphasizes that risk stratification based on age, smoking history, and red blood cell quantification is essential for determining the appropriate diagnostic pathway. While gross hematuria carries a 13% risk of malignancy, microscopic hematuria presents a much lower risk of approximately 3%. High-risk patients require cystoscopy and contrasted upper tract imaging, whereas low-risk individuals may safely undergo shared decision-making, often opting for observation or repeat urinalysis. Persistent hematuria after initial negative testing warrants further investigation, though routine cytology is generally unnecessary unless specific risk factors or irritative voiding symptoms are present.